WO2004108765A3 - Extracellular aspergillus polypeptides - Google Patents

Extracellular aspergillus polypeptides Download PDF

Info

Publication number
WO2004108765A3
WO2004108765A3 PCT/DK2004/000407 DK2004000407W WO2004108765A3 WO 2004108765 A3 WO2004108765 A3 WO 2004108765A3 DK 2004000407 W DK2004000407 W DK 2004000407W WO 2004108765 A3 WO2004108765 A3 WO 2004108765A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
fragments
relates
extracellular
antibodies
Prior art date
Application number
PCT/DK2004/000407
Other languages
French (fr)
Other versions
WO2004108765A2 (en
Inventor
Andrew Roche
Martin Chr Hansen
Inge D Villsen
Petra Schrotz-King
Jeanette Henningsen
Trine Louise Lund Joergensen
Original Assignee
Ace Biosciences As
Andrew Roche
Martin Chr Hansen
Inge D Villsen
Petra Schrotz-King
Jeanette Henningsen
Trine Louise Lund Joergensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ace Biosciences As, Andrew Roche, Martin Chr Hansen, Inge D Villsen, Petra Schrotz-King, Jeanette Henningsen, Trine Louise Lund Joergensen filed Critical Ace Biosciences As
Priority to JP2006515711A priority Critical patent/JP2007535897A/en
Priority to EP04736511A priority patent/EP1636269A2/en
Priority to US10/559,952 priority patent/US20060241288A1/en
Priority to CA002528851A priority patent/CA2528851A1/en
Priority to AU2004245174A priority patent/AU2004245174A1/en
Publication of WO2004108765A2 publication Critical patent/WO2004108765A2/en
Publication of WO2004108765A3 publication Critical patent/WO2004108765A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

The present invention relates to extracellular polypeptides of Aspergillus fumigatus, to fragments of these polypeptides, to compositions comprising such polypeptides and fragments and to exposed domains and epitopes of these polypeptides. The invention also relates to the use of these polypeptides and fragments for immunisation and for production of antibodies, and to antibodies that recognize and bind the polypeptides. Furthermore, the invention relates to methods of identifying binding partners and inhibitors, and to methods of preventing, treating and diagnosing Aspergillus infections.
PCT/DK2004/000407 2003-06-10 2004-06-10 Extracellular aspergillus polypeptides WO2004108765A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006515711A JP2007535897A (en) 2003-06-10 2004-06-10 Extracellular Aspergillus polypeptide
EP04736511A EP1636269A2 (en) 2003-06-10 2004-06-10 Extracellular aspergillus polypeptides
US10/559,952 US20060241288A1 (en) 2003-06-10 2004-06-10 Extracellular aspergillus polypeptides
CA002528851A CA2528851A1 (en) 2003-06-10 2004-06-10 Extracellular aspergillus polypeptides
AU2004245174A AU2004245174A1 (en) 2003-06-10 2004-06-10 Extracellular Aspergillus polypeptides

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200300862 2003-06-10
DKPA200300862 2003-06-10
US47735503P 2003-06-11 2003-06-11
US60/477,355 2003-06-11
US48245103P 2003-06-26 2003-06-26
DKPA200300968 2003-06-26
DKPA200300968 2003-06-26
US60/482,451 2003-06-26

Publications (2)

Publication Number Publication Date
WO2004108765A2 WO2004108765A2 (en) 2004-12-16
WO2004108765A3 true WO2004108765A3 (en) 2005-07-14

Family

ID=33514773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000407 WO2004108765A2 (en) 2003-06-10 2004-06-10 Extracellular aspergillus polypeptides

Country Status (5)

Country Link
EP (1) EP1636269A2 (en)
JP (1) JP2007535897A (en)
AU (1) AU2004245174A1 (en)
CA (1) CA2528851A1 (en)
WO (1) WO2004108765A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811562A2 (en) 2007-05-07 2014-12-09 Novartis Ag ORGANIC COMPOUNDS
DE102007031947A1 (en) * 2007-07-06 2009-01-08 Helmholtz-Zentrum Für Umweltforschung Gmbh - Ufz Allergens from Aspergillus versicolor and methods for detecting an indoor mold allergy
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
US8236808B2 (en) 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US20140242085A1 (en) * 2011-08-12 2014-08-28 Medical & Biological Laboratories Co., Ltd. Methods and composition for testing, preventing, and treating aspergillus fumigatus infection
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
ES2558457T3 (en) 2011-09-16 2016-02-04 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
BR112016023967A2 (en) 2014-04-24 2017-08-15 Novartis Ag pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
JP6433509B2 (en) 2014-04-24 2018-12-05 ノバルティス アーゲー Aminopyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2015162456A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
CN107164478A (en) * 2017-05-27 2017-09-15 山西维尔生物乳制品有限公司 A kind of probe, primer and genetic chip for differentiating aspergillus fumigatus
US20200383960A1 (en) 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
JP2022547427A (en) 2019-08-28 2022-11-14 ノバルティス アーゲー Substituted 1,3-phenylheteroaryl derivatives and their use in treating disease
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOUCHARA J P ET AL: "Adhesion and pathogenicity in Aspergillus infections", MEDECINE ET MALADIES INFECTIEUSES 1999 FRANCE, vol. 29, no. 11, 1999, pages 705 - 711, XP002307496, ISSN: 0399-077X *
DATABASE Geneseq [online] 24 December 1998 (1998-12-24), "Aspergillus fumigatus protein 3.", XP002307501, retrieved from EBI accession no. GSN:AAW69392 Database accession no. AAW69392 *
DATABASE UniProt [online] 30 May 2000 (2000-05-30), "3-isopropylmalate dehydrogenase B (EC 1.1.1.85) (Beta-IPM dehydrogenase B) (IMDH B) (3-IPM-DH B).", XP002307500, retrieved from EBI accession no. UNIPROT:LE3B_ASPNG Database accession no. LE3B_ASPNG *
HANSEN MIA YOUNG ET AL: "Allergens in Aspergillus fumigatus: I. Characterization of two different allergen extracts and evaluation of their stability and the importance of carbohydrate for IgE binding", ALLERGY (COPENHAGEN), vol. 49, no. 4, 1994, pages 235 - 241, XP009040600, ISSN: 0105-4538 *
REIJULA K E ET AL: "MONOCLONAL ANTIBODIES BIND IDENTICALLY TO BOTH SPORES AND HYPHAE OF ASPERGILLUS-FUMIGATUS", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 22, no. 5, 1992, pages 547 - 553, XP001184000, ISSN: 0954-7894 *
WILLIAMS B A ET AL: "Isolation by genetic complementation of two differentially expressed genes for beta-isopropylmalate dehydrogenase from Aspergillus niger", CURRENT GENETICS, vol. 30, no. 4, 1996, pages 305 - 311, XP002307495, ISSN: 0172-8083 *

Also Published As

Publication number Publication date
CA2528851A1 (en) 2004-12-16
WO2004108765A2 (en) 2004-12-16
EP1636269A2 (en) 2006-03-22
AU2004245174A1 (en) 2004-12-16
JP2007535897A (en) 2007-12-13

Similar Documents

Publication Publication Date Title
WO2004108765A3 (en) Extracellular aspergillus polypeptides
WO2003034903A3 (en) Psma antibodies and protein multimers
EP2400021A3 (en) ErbB3 based methods and compositions for treating neoplasms
WO2006099698A3 (en) Novel anti-plgf antibody
WO2007092640A3 (en) Antibodies that bind par-2
WO2006012621A3 (en) Compositions and methods for regulating the alternative pathway of complement
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
MX2009013824A (en) Antigen binding proteins that bind par-2.
WO2007098420A8 (en) Peptides that block the binding of igg to fcrn
MX2009012949A (en) Humanized antibodies which bind to aî² (1-42) globulomer and uses thereof.
WO2005063816A3 (en) Monovalent antibody fragments useful as therapeutics
WO2005103083A8 (en) Anti-cd38 human antibodies and uses therefor
WO2008031061A3 (en) Anti-activin a antibodies and uses thereof
WO2006017538A3 (en) Hk1-binding proteins
WO2003061559A3 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
WO2011002968A3 (en) Polypeptides and method of treatment
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
MX2022000325A (en) Dll3-targeting antibodies and uses thereof.
WO2004005890A3 (en) Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
WO2001087233A3 (en) Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions and method of use thereof
WO2002053104A3 (en) Use of catecholamine reuptake inhibitors to enhance memory
WO2007084107A3 (en) Monoclonal antibodies that neutralize anthrax protective antigen (pa) toxin
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2528851

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006515711

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004736511

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004245174

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004245174

Country of ref document: AU

Date of ref document: 20040610

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004736511

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006241288

Country of ref document: US

Ref document number: 10559952

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10559952

Country of ref document: US